C4 Therapeutics, Inc. (CCCC)
After hours:
| Previous Close | 6.47 |
| Open | 6.30 |
| Bid | 6.22 x 300 |
| Ask | 6.28 x 300 |
| Day's Range | 6.15 - 6.34 |
| 52 Week Range | 1.06 - 11.88 |
| Volume | |
| Avg. Volume | 2,535,240 |
| Market Cap | 428.068M |
| Beta (5Y Monthly) | 3.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
GlobeNewswireC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024. Fireside Chat Details:Event: Stifel 2024 Targeted Oncology ForumDate/Time: Tuesday, April 16, 2024 from 10:30 am ET – 10:55 am ET
- GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant m
Insider MonkeyHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. During the final months of the year, optimism prevailed due to news of reducing inflation and the potential for lower interest rates in 2024. The fund returned 13.64% (net) […]
